Apnimed has closed its upsized initial public offering, raising gross proceeds of $220.8 million before deducting underwriting discounts and offering expenses. The late-stage clinical pharmaceutical company sold an aggregate of 13,800,000 shares of common stock at $16.00 per share, which included the full exercise of the underwriters' overallotment option to purchase an additional 1,800,000 shares. The shares began trading on the Nasdaq Global Select Market on July 31, 2026, under the ticker symbol APMD. BofA Securities, Evercore ISI, Cantor, and LifeSci Capital acted as joint book-running managers for the offering.
Bank of America Corp
Evercore Partners Inc
Apnimed, Inc. Common StockApnimed closed its upsized IPO, raising $220.8 million in gross proceeds.